Updated: 5 days ago
Medically reviewed by Dr. Wang
Key Takeaways |
|
Introduction
CAR-T for stomach cancer in China is an approved option for a defined group of patients; CAR-T stands for chimeric antigen receptor T-cell therapy. Before travelling, families need to confirm the cancer’s test results, the patient’s fitness, an appropriate treatment centre and a realistic plan for time and cost. Treatment does not work for everyone, and disease can progress while the patient’s cells are being prepared.
Who Is Eligible for CAR-T for Stomach Cancer in China?
The approved indication is advanced CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma after at least two prior treatment lines have failed. Ask the oncologist to list each treatment regimen and why it stopped; treatment cycles are not separate treatment lines.
China’s National Medical Products Administration (NMPA) announced the approval on 22 June 2026. Government reporting identifies satri-cel as the first CAR-T therapy approved for a solid tumour.
The receiving specialist must also assess whether the patient can tolerate cell collection, preparatory treatment and monitoring. Ask specifically about current symptoms, nutrition, blood counts, organ function, infection and how quickly the cancer is changing. Research protocols assess these issues, but the hospital must apply the current commercial prescribing information to the individual case.
What Benefit Should Families Realistically Expect?
The trial supports a period of improved disease control, with uncertainty about the overall-survival benefit. These results describe groups of patients and cannot predict an individual outcome.
Outcome in CT041-ST-01 | Satri-cel | Physician’s choice | Interpretation | Source |
Median progression-free survival | 3.25 months | 1.77 months | Hazard ratio 0.37; statistically significant | [3] |
Median overall survival | 7.92 months | 5.49 months | Not statistically significant | [3] |
Progression-free survival measures time until cancer worsens or the patient dies. A median describes the midpoint of a group’s results. Discuss whether the possible benefit fits the patient’s priorities, symptoms and ability to undergo treatment.
Table of Content
What Tests Are Needed Before CAR-T for Stomach Cancer in China?
Start with complete CLDN18.2 and HER2 pathology reports, then let the receiving specialist identify any missing tests. Do not arrange another biopsy or ship tissue until the receiving laboratory confirms what it needs.
CLDN18.2 is assessed in tumour tissue using immunohistochemistry (IHC), which shows protein staining. A sequencing report alone does not establish this staining result. For HER2, an equivocal IHC result needs in situ hybridisation (ISH) to help establish the final status; fluorescence in situ hybridisation (FISH) is one form of ISH.
Test or record | What to provide | Why it matters / source |
CLDN18.2 IHC | Full report showing the assay, staining intensity, percentage of tumour cells stained, and specimen date and site | Supports the receiving laboratory's interpretation of the result. |
HER2 testing | IHC score and any ISH result; an IHC score of 2+ needs clarification with ISH | Equivocal staining alone does not establish a negative result. |
Original pathology | Diagnosis, biopsy or operation report, and information about available tissue blocks or unstained slides | Helps confirm tumour type and whether existing material can support further testing. |
Current disease assessment | Recent scan reports and the original scan files, treatment history and a current symptom summary | Helps the hospital assess disease burden and fitness. |
Clinical tests | Available blood counts, liver and kidney tests, infection screening and other tests requested by the specialist | The hospital determines the required tests and how recent they must be. |
Does CLDN18.2 Positivity Automatically Mean Eligibility?
No. The assay, staining threshold and the rest of the clinical assessment all matter. Different studies use different definitions of “positive.”
Finding | Verified figure | How to interpret it |
Satri-cel trial threshold | IHC ≥2+ in ≥40% of tumour cells | VERIFY current commercial criteria and assay |
CLDN18.2 prevalence in pooled advanced gastric/GEJ cancer screening populations | 38.4%: 1,730 of 4,507 assessable patients | Used a different threshold: at least 75% of tumour cells with moderate-to-strong staining. This is not the proportion eligible for satri-cel. |
Also send any other biomarker reports already available. The review should consider appropriate alternatives, particularly when the current pathology or the patient’s condition does not support satri-cel.
What Should We Put in the Case-Review Folder?
Send a complete, dated record of the diagnosis and treatment so the hospital can identify gaps before travel.
Include pathology and biomarker reports; recent scans and original imaging files; a list of previous regimens with dates, response and reasons for stopping; current medicines and allergies; recent laboratory results; and a short summary of eating, weight change, symptoms and daily activity. Keep the original-language documents alongside any translations, and ask the receiving team which documents need certified translation. This is a preparation checklist; the accepting hospital will confirm its own requirements.
Confirm Eligibility Before You Book Flights
Before you book flights, confirm eligibility: send the CLDN18.2 and HER2 pathology report for a Preliminary Case Review and get matched with up to 3 authorised hospitals.
ChinaCureLink reviews the diagnosis, pathology, biomarkers and previous treatments, identifies suitable treatment paths for specialist assessment, and helps match the case with up to three relevant Chinese hospitals and specialists before any travel decision. Matching depends on medical suitability, verified product qualification and hospital acceptance.
Start with the medical enquiry form and request instructions for submitting your pathology reports.
How Can International Patients Access CAR-T for Stomach Cancer in China, Step by Step?
Access should move from records review to verified hospital acceptance, then to a written treatment plan and travel arrangements. Chinese product approval does not establish an available appointment or treatment place for a particular international patient.
Review the records remotely. Confirm the diagnosis, biomarkers, previous treatment lines and current clinical condition. Identify missing pathology or scans before paying for travel.
Verify the hospital and product route. Check the hospital’s licence and its current qualification for satri-cel. Ask whether the proposed care uses the approved commercial product or a research protocol.
Obtain a written plan. Request the proposed treatment sequence, estimated dates, itemised fees, payment and cancellation terms, and confirmation that the hospital can accept an international patient. Complete any insurer pre-authorisation.
Confirm the cell-collection arrangements. The team decides where collection can occur and checks fitness again. Leukapheresis collects blood cells from which the patient’s T cells are prepared.
Plan care during manufacturing. The oncologist may prescribe bridging therapy to control the cancer while the cells are prepared. Coordinate this with the home oncologist; do not stop or change treatment independently.
Reassess before treatment. The hospital checks continued suitability and product release. Preparatory chemotherapy, called lymphodepletion, precedes infusion under the treating team’s plan.
Complete monitoring and the return-home handover. Obtain the observation plan, emergency contact details, discharge information and follow-up responsibilities. The clinical team decides when travel home is appropriate.
How Do We Check That a Hospital Is Authorised?
Verify both the hospital’s licence and its qualification for the specific satri-cel product. Ask to see the current list of qualified institutions published by the product’s marketing authorisation holder.
Shanghai’s CAR-T rules require its marketing authorisation holders to assess collection and treatment institutions, arrange training and quality agreements, and publish qualified-institution lists. This is relevant to satri-cel’s Shanghai-based authorisation holder. It is not a single national accreditation proving that any hospital can administer every CAR-T product.
Ask the hospital to confirm the named product, collection and infusion locations, supervising clinical team, and how it manages serious complications. Verify international-patient acceptance and an available treatment slot directly with the receiving team.
Why Can a Patient Lose the Opportunity During the Wait?
The cancer can worsen between assessment and infusion, even after cells have been collected. Ask what treatment and monitoring will continue while manufacturing proceeds, and what the alternative care plan is if infusion becomes unsuitable.
Trial observation | Verified result | Source |
Not infused after collection | 16 of 104; 5 recorded as progression; other reasons also occurred | [3], flowchart |
Before committing funds, obtain written terms covering manufacturing failure, deterioration before infusion, cancellation and any non-refundable charges. No case-review service can guarantee that a patient will remain fit for treatment.
How Long Does CAR-T for Stomach Cancer in China Take, and What Does It Cost?
The accepting hospital must confirm the total stay and an individual satri-cel quotation. The trip needs to account for assessment, cell collection, manufacturing, preparatory treatment, infusion, observation and recovery.
How Should We Plan the Time Away From Home?
Use trial timing only as context, and request current dates from the hospital.
Timing or schedule item | What is known | Source / verification |
Collection to first infusion | Median 28 days; middle half of patients, 25–33 days | [3]; trial timing only |
Infusions studied | Up to 3 | [3]; commercial schedule VERIFY |
Review, testing and scheduling | VERIFY | Written confirmation from the accepting hospital required |
Inpatient stay and nearby accommodation | VERIFY | Depends on the care plan and recovery |
Total time in China and earliest flight home | VERIFY | Requires the treating team’s assessment |
Ask whether the patient must remain near the centre while cells are prepared, whether repeat treatment is anticipated, and how a longer recovery would affect accommodation and caregiver arrangements. Obtain the documents needed to check entry requirements for the patient’s passport and expected stay. Keep the return booking flexible until the team confirms that travel is appropriate.
What Should a Stomach Cancer CAR-T Cost China Quotation Include?
Request an itemised quote naming satri-cel and stating exactly what is included. A general CAR-T estimate cannot establish the final cost of this product.
Cost item | Amount or status | Source / verification |
General China CAR-T planning figure supplied in the brief | About US100,000–US150,000 total — VERIFY | Brief-supplied estimate; no qualifying source established it as a satri-cel total. It must be replaced or substantiated before publication. |
Individual satri-cel treatment total | VERIFY — written hospital quotation required | No verified product-specific total established |
Further infusions, complications or prolonged care | VERIFY — inclusion or separate charges | Obtain explicit terms; do not assume inclusion |
Travel, accommodation, caregiver and coordination expenses | VERIFY — itemise separately | Confirm which expenses the hospital quote covers |
The quote should identify pathology review, additional tests, collection, manufacturing, bridging therapy if prescribed, lymphodepletion, infusion, hospital care, medicines, follow-up and management of complications. Ask which charges remain payable if the patient cannot proceed.
Request a dated quote in its billing currency. If comparing it with a home-currency budget, record the conversion date and bank charges separately.
What Should Families Check With Their Insurer?
Seek written pre-authorisation for the named product and hospital before making a financial commitment. Declare that the purpose of travel is treatment, and ask about complications, intensive care, evacuation and follow-up after returning home.
Home country | What to check | Source |
Singapore | MediShield Life excludes overseas medical treatment. Check private-policy benefits and any other financing route separately. | [12] |
Australia | Medicare does not cover overseas care. Ask the private insurer about the named procedure and hospital; ordinary travel insurance should not be assumed to pay. | [10] |
New Zealand | Basic travel insurance rarely covers medical tourism. Confirm procedure-specific cover, complications and medical evacuation. | [11] |
Malaysia, Thailand, Vietnam and Indonesia | Ask the insurer or benefits administrator about planned overseas cellular therapy, prior approval, hospital restrictions and exclusions. Individual coverage remains VERIFY. | Policy-specific enquiry; no blanket coverage claim made |
What Are the Risks and Side Effects of CAR-T for Stomach Cancer in China?
Inflammatory reactions, low blood counts, infection and digestive complications require specialist monitoring. Treatment takes place in a centre equipped to recognise and manage serious deterioration.
Cytokine release syndrome (CRS) is an excessive inflammatory response. It can cause fever, a rapid heartbeat, low blood pressure and difficulty breathing. The team monitors for it and provides treatment when needed; severe reactions can be life-threatening.
Safety finding in satri-cel recipients | Result | Source |
CRS, any grade | 84/88; about 95% | [3] |
CRS, grade 3 or higher | 4/88: 4.5%; paper rounds to 5% | [3] |
Grade 3 or higher treatment-emergent adverse events | 87/88: 99% | Includes preparation and infusion. [3] |
Some serious complications can be fatal. The team should also explain infection precautions, stomach-lining injury or bleeding, and neurological warning signs. New confusion, unusual sleepiness or speech changes require urgent assessment. Risks described for CAR-T generally should not be mistaken for a product-specific satri-cel frequency.
When Should We Contact Our Doctor About CAR-T for Stomach Cancer in China?
Keep the home oncologist involved during planning and after returning, and report worsening symptoms promptly. During treatment in China, use the receiving hospital’s clinical contact arrangements.
Seek urgent medical assessment for fever or chills after treatment, new breathing difficulty, fainting, confusion, unusual drowsiness or difficulty speaking. Tell the team that CAR-T treatment has been given or is being planned.
Severe abdominal pain, repeated vomiting, increasing abdominal swelling or inability to pass stool or gas can signal obstruction. Vomiting blood or having black, tarry stools also requires urgent medical attention.
For severe symptoms, seek local emergency care immediately and contact the treating centre. Do not wait for a facilitator’s reply or a routine appointment. Before returning home, arrange who will review blood tests, medicines, symptoms and follow-up scans.
How ChinaCureLink Can Help
ChinaCureLink starts with the medical case and helps coordinate an appropriate hospital assessment before travel. We are a Medebound HEALTH company, an independent medical facilitator and patient advocate, and we do not represent only one hospital.
“We don’t begin with the hospital. We begin with the medical case.”
Our role includes:
Case review: Reviewing the diagnosis, pathology, biomarkers and previous treatments to identify treatment paths for specialist assessment.
Hospital coordination: Helping match the case with up to three relevant Chinese hospitals and specialists, with product qualification and acceptance checked.
Online consultation before travel: Coordinating a discussion of suitability, alternatives, expected benefit and the proposed treatment plan.
Coordination support: Helping organise records, appointments, clarification of costs and communication about the transition home.
The treating hospital makes the final eligibility and treatment decisions. A preliminary review does not guarantee admission, infusion or benefit.
Considering This Treatment in China?
Before you book flights, confirm eligibility: send the CLDN18.2 and HER2 pathology report for a Preliminary Case Review and get matched with up to 3 authorised hospitals.
We review the diagnosis, pathology, biomarkers and previous treatments, identify suitable treatment paths for specialist assessment, and help match the case with up to three relevant Chinese hospitals and specialists before any travel decision is made. Hospital options depend on medical suitability, verified satri-cel qualification and acceptance.
Start with the medical enquiry form and request instructions for submitting your pathology reports.
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Can Foreigners Get CAR-T for Stomach Cancer in China?
Foreign patients need individual acceptance from a hospital qualified to provide satri-cel. The Chinese approval defines the medical indication, but does not confirm that a particular centre can accept an overseas patient. Obtain a written eligibility assessment, confirmation of current product-specific qualification, and a treatment and monitoring plan before booking travel.
Is Satri-Cel Available Outside China?
China’s marketing approval is confirmed. Satri-cel has also been studied outside China, but a research listing does not establish routine availability or an open treatment place. Ask your local oncologist to check current authorisation, recruitment or lawful special-access arrangements in your country. This guide does not confirm a commercial treatment route outside China.
Does Insurance Cover CAR-T for Stomach Cancer in China?
Coverage is policy-specific and should be confirmed in writing before payment. Ask about planned overseas treatment, the named satri-cel product and hospital, prior authorisation, complications, intensive care and medical evacuation. Chinese regulatory approval does not by itself establish insurance coverage. Ordinary travel insurance should not be assumed to cover a trip made for treatment.
What If My Stomach Cancer Is HER2-Positive?
HER2-positive stomach cancer falls outside the indication described in the NMPA satri-cel approval announcement. Ask your oncologist to review appropriate alternatives and whether an older or uncertain pathology result needs clarification. An equivocal HER2 immunohistochemistry result requires the appropriate follow-up testing; a facilitator should not reinterpret it as negative to arrange treatment.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
Numbered and dated sources
National Medical Products Administration. Satri-cel approval announcement, “国家药监局批准舒瑞基奥仑赛注射液上市.” 22 June 2026.Original announcement.
Pudong government. Government report identifying satri-cel as the first approved CAR-T therapy for a solid tumour. 24 June 2026.Government report.
Qi C, Liu C, Peng Z, et al. CT041-ST-01 randomised phase 2 trial. The Lancet. 2025;405:2049–2060. Published online 31 May 2025; issue date 7 June 2025.DOI: 10.1016/S0140-6736(25)00860-8; PubMed record.
College of American Pathologists, American Society for Clinical Pathology and American Society of Clinical Oncology. HER2 testing guideline for gastro-oesophageal adenocarcinoma. 2016; current guidance page accessed 9 October 2026Guideline and testing algorithm.
Shitara K, Xu RH, Ajani JA, et al. Global CLDN18.2 prevalence study in advanced gastric/GEJ adenocarcinoma. Gastric Cancer. 2024;27:1058–1068. Published 2 July 2024.DOI: 10.1007/s10120-024-01518-1.
Shanghai Municipal Medical Products Administration. Autologous CAR-T supervision rules, including institution qualification and publication of qualified-centre lists. Issued 26 August 2024; published 28 August 2024.Regulation.
National Cancer Institute. CAR-T process and adverse-effect overview. Updated 26 February 2025. CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers.
National Cancer Institute. Cytokine release syndrome definition. Accessed 9 October 2026.NCI Dictionary of Cancer Terms.
National Cancer Institute. Bowel obstruction and cancer. Updated 16 May 2025.Symptoms and urgent assessment.
Australian Government, Smartraveller. Going overseas for a medical procedure. Accessed 9 October 2026.Costs, insurance and preparation.
New Zealand Government, SafeTravel. Medical tourism. Accessed 9 October 2026.Insurance, travel preparation and follow-up.
Singapore Central Provident Fund Board. What MediShield Life covers you for; overseas-treatment exclusion. Updated 7 October 2026; accessed 9 October 202Coverage and exclusions.
National Cancer Institute. CT041-ST-02 / NCT04404595 investigational trial record. Accessed 9 October 2026; overall status shown as closed to accrual. Used for research-context assessment and overseas trial history, not commercial-label criteria or an available treatment offer.Trial record.
NHS. Vomiting blood. Last reviewed 18 August 2025.Urgent warning signs.
